Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)
NCT00280566
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Adults meeting DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) criteria for Bipolar I Disorder (currently with manic or mixed symptoms)
Ultra rapid cyclers and subjects with significant cardiovascular disease including history
of QT prolongation and/or congenital long QT syndrome
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Birmingham, Alabama
- Birmingham, Alabama
- Birmingham, Alabama
- Scottsdale, Arizona
- Little Rock, Arkansas
- Costa Mesa, California
- Los Angeles, California
- National City, California
- Sacramento, California
- San Diego, California
- Temecula, California
- Temecula, California
- Altamonte Springs, Florida
- Fort Lauderdale, Florida
- Fort Myers, Florida
- Jacksonville, Florida
- Maitland, Florida
- Miami, Florida
- Miami, Florida
- North Miami, Florida
- Orlando, Florida
- Tavares, Florida
- Decatur, Georgia
- Smyrna, Georgia
- Honolulu, Hawaii
- Des Plaines, Illinois
- Libertyville, Illinois
- Naperville, Illinois
- Naperville, Illinois
- Oak Brook, Illinois
- Schaumburg, Illinois
- Terre Haute, Indiana
- Topeka, Kansas
- Wichita, Kansas
- Lexington, Kentucky
- Owensboro, Kentucky
- Baltimore, Maryland
- Rockville, Maryland
- Pittsfield, Massachusetts
- Taunton, Massachusetts
- Olive Branch, Mississippi
- Ridgeland, Mississippi
- St. Charles, Missouri
- Lincoln, Nebraska
- Lincoln, Nebraska
- Omaha, Nebraska
- Las Vegas, Nevada
- Nashua, New Hampshire
- Paramus, New Jersey
- Teaneck, New Jersey
- Buffalo, New York
- Olean, New York
- Rochester, New York
- Raleigh, North Carolina
- Cincinnati, Ohio
- Columbus, Ohio
- Toledo, Ohio
- Bethany, Oklahoma
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Media, Pennsylvania
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
- Memphis, Tennessee
- Arlington, Texas
- Austin, Texas
- Bellaire, Texas
- Dallas, Texas
- Dallas, Texas
- DeSoto, Texas
- Houston, Texas
- Houston, Texas
- Houston, Texas
- Santiago, RM
- Santiago,
- Angouleme,
- Brest Naval,
- Douai,
- Mulhouse,
- Berlin,
- Berlin,
- Cham,
- Essen,
- Ciudad de Guatemala,
- Guatemala,
- New Territories,
- Ellisbridge, Ahmedabad
- Tirupati, Andhra Pradesh
- Bangalore, Karnataka
- Mysore, Karnataka
- Chennai, Tamil Nadu
- Ludhiana,
- Pune,
- Catania,
- Firenze,
- Parma,
- Pisa,
- Mexico, DF
- Zapopan, Jalisco
- Arkhangelskaya Obl, Primorsky Raion,
- Khotkovo,
- Barcelona,
- Barcelona,
- Madrid,
- Taipei,
- Taipei,
- Caracas, Distrito Capital
- Caracas, Distrito Capital
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed) | |||
Official Title ICMJE | A Phase 3, Randomized, 6-Month, Double-Blind Trial in Subjects With Bipolar I Disorder to Evaluate the Continued Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer (vs Placebo Plus a Mood Stabilizer) Following a Minimum of 2 Months of Response to Open-Label Treatment With Both Agents | |||
Brief Summary | The purpose of this study is to determine if ziprasidone plus a mood stabilizer will continue to be a safe and effective treatment regimen for adults with Bipolar I Disorder (manic or mixed symptoms) after they have achieved 8 consecutive weeks of symptom improvement on the regimen. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment | |||
Condition ICMJE |
| |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry. 2010 Feb;71(2):130-7. doi: 10.4088/JCP.09m05482yel. Epub 2010 Jan 26. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 584 | |||
Original Enrollment ICMJE | 230 | |||
Actual Study Completion Date ICMJE | May 2008 | |||
Actual Primary Completion Date | May 2008 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria: Adults meeting DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) criteria for Bipolar I Disorder (currently with manic or mixed symptoms) Exclusion Criteria: Ultra rapid cyclers and subjects with significant cardiovascular disease including history of QT prolongation and/or congenital long QT syndrome | |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Chile, France, Germany, Guatemala, Hong Kong, India, Italy, Mexico, Russian Federation, Spain, Taiwan, United States, Venezuela | |||
Removed Location Countries | Sweden | |||
Administrative Information | ||||
NCT Number ICMJE | NCT00280566 | |||
Other Study ID Numbers ICMJE | A1281137 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer Inc | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | January 2010 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |